{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:05:30Z","timestamp":1778929530375,"version":"3.51.4"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-024-02071-x","type":"journal-article","created":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T08:01:32Z","timestamp":1728201692000},"page":"225-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The safety of corticosteroid therapy in IGA nephropathy: analysis of a real-life Italian cohort"],"prefix":"10.1093","volume":"38","author":[{"given":"Ivano","family":"Baragetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-2323","authenticated-orcid":false,"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Alberici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Amendola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Ponti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Pani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Rollino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Giannese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Boscutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annasara","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Colturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Brunori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lazzarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausta","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Italian Group of Steroids in IgAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,6]]},"reference":[{"issue":"1","key":"2071_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ki.2015.322","volume":"89","author":"SJ Barbour","year":"2016","unstructured":"Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC, Oxford Derivation, N. A, Consortia V, Oxford Derivation North American, V, Consortia V (2016) The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 89(1):167\u2013175","journal-title":"Kidney Int"},{"issue":"9156","key":"2071_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353(9156):883\u2013887","journal-title":"Lancet"},{"issue":"1","key":"2071_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15(1):157\u2013163","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"2071_CR4","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F, Schena FP (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24(12):3694\u20133701","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2071_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","volume":"53","author":"J Lv","year":"2009","unstructured":"Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H (2009) Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 53(1):26\u201332","journal-title":"Am J Kidney Dis"},{"key":"2071_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.539545","volume":"11","author":"S Han","year":"2020","unstructured":"Han S, Yao T, Lu Y, Chen M, Xu Y, Wang Y (2020) Efficacy and safety of immunosuppressive monotherapy agents for IgA nephropathy: a network meta-analysis. Front Pharmacol 11:539545","journal-title":"Front Pharmacol"},{"issue":"4","key":"2071_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40620-014-0165-x","volume":"28","author":"XH Shen","year":"2015","unstructured":"Shen XH, Liang SS, Chen HM, Le WB, Jiang S, Zeng CH, Zhou ML, Zhang HT, Liu ZH (2015) Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol 28(4):441\u2013449","journal-title":"J Nephrol"},{"issue":"12","key":"2071_CR8","doi-asserted-by":"publisher","first-page":"eadd6734","DOI":"10.1126\/sciadv.add6734","volume":"9","author":"Y Nihei","year":"2023","unstructured":"Nihei Y, Haniuda K, Higashiyama M, Asami S, Iwasaki H, Fukao Y, Nakayama M, Suzuki H, Kikkawa M, Kazuno S, Miura Y, Suzuki Y, Kitamura D (2023) Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv 9(12):eadd6734","journal-title":"Sci Adv"},{"issue":"23","key":"2071_CR9","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J, Investigators, STOP-IgAN Investigators (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373(23):2225\u20132236","journal-title":"N Engl J Med"},{"issue":"5","key":"2071_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Wang HY, Perkovic V, Group, T. S (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318(5):432\u2013442","journal-title":"JAMA"},{"key":"2071_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02036-1","author":"L Del Vecchio","year":"2024","unstructured":"Del Vecchio L, Marco A, Comolli S, Peiti S, Rimoldi C, Locatelli F (2024) Drugs in development to treat IgA nephropathy. Drugs. https:\/\/doi.org\/10.1007\/s40265-024-02036-1","journal-title":"Drugs"},{"issue":"10405","key":"2071_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J, NefIgArd trial investigators (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402(10405):859\u2013870","journal-title":"Lancet"},{"issue":"6","key":"2071_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000489580","volume":"47","author":"Y Lin","year":"2018","unstructured":"Lin Y, Jia J, Guo Y, He D, Zhang Y, Wang F, Yan T, Liu Y, Lin S (2018) Corticosteroid for IgA nephropathy: are they really therapeutic? Am J Nephrol 47(6):385\u2013394","journal-title":"Am J Nephrol"},{"issue":"1","key":"2071_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40620-015-0248-3","volume":"29","author":"C Pozzi","year":"2016","unstructured":"Pozzi C (2016) Treatment of IgA nephropathy. J Nephrol 29(1):21\u201325","journal-title":"J Nephrol"},{"issue":"6","key":"2071_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2215\/CJN.02300215","volume":"11","author":"C Sarcina","year":"2016","unstructured":"Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P, Del Vecchio L, Alberghini E, Buzzi L, Baragetti I, Pozzi C (2016) Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol 11(6):973\u2013981","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"2071_CR16","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, Group, T. S (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327(19):1888\u20131898","journal-title":"JAMA"},{"issue":"4","key":"2071_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ekir.2017.02.003","volume":"2","author":"Q Cai","year":"2017","unstructured":"Cai Q, Xie X, Wang J, Shi S, Liu L, Chen Y, Lv J, Zhang H (2017) Severe Adverse effects associated with corticosteroid treatment in patients with IgA nephropathy. Kidney Int Rep 2(4):603\u2013609","journal-title":"Kidney Int Rep"},{"key":"2071_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000422413","volume":"104","author":"BA Julian","year":"1993","unstructured":"Julian BA, Barker C (1993) Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Contrib Nephrol 104:198\u2013206","journal-title":"Contrib Nephrol"},{"issue":"3","key":"2071_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2215\/CJN.01120905","volume":"1","author":"N Yoshikawa","year":"2006","unstructured":"Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H (2006) Japanese Pediatric Ig, A. N. T. S. G. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol 1(3):511\u2013517","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2071_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s101570300006","volume":"7","author":"Y Kanno","year":"2003","unstructured":"Kanno Y, Witt M, Okada H, Nemoto H, Sugahara S, Nakamoto H, Suzuki H (2003) A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial. Clin Exp Nephrol 7(1):48\u201351","journal-title":"Clin Exp Nephrol"},{"key":"2071_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/CEOR.S157673","volume":"10","author":"M DiBonaventura","year":"2018","unstructured":"DiBonaventura M, Nicolucci A, Meincke H, Le Lay A, Fournier J (2018) Obesity in Germany and Italy: prevalence, comorbidities, and associations with patient outcomes. Clinicoecon Outcomes Res 10:457\u2013475","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"2071_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejia-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J (2021) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100(4):753\u2013779","journal-title":"Kidney Int"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02071-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02071-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02071-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:10Z","timestamp":1777564390000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/1\/225\/8304788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,6]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["2071"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02071-x","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,6]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lucia Del Vecchio had speaker fees at meeting with indirect support of Vifor, AstraZeneca, Bayer, Amgen, Astellas; she participated to an Advisory board for Travere; she is National leader of the PROTECT study. Federico Alberici received Consulting fees from CSL-Vifor, Travere Therapeutics, Otsuka and Speaker fees from CSL-Vifor, Travere Therapeutics, Otsuka. Giuliano Boscuttihad Consulting fees from Alexion Pharma, Glaxo-Smith-Kline and Speaker fees at meeting with indirect support of Vifor Pharma, AstraZeneca, Alexion Pharma, Astellas Pharma. He received support for attending meetings from Bayer, Alnilam S.p.a., Sandoz S.p.a., Estor S.p.a. Ivano Baragetti, Francesca Ferrario, Andrea Amendola, Elisa Russo\n                      ,\n                      Serena Ponti, Anna Maria Di Palma\n                      ,\n                      Antonello Pani, Cristiana Rollino\n                      ,\n                      Domenico Giannese, Annasara, Carla Colturi, Giuliano Brunori, Roberta Lazzarin, Fausta Catapano, Mario Cozzolino, Sandro Feriozzi\n                      ,\n                      Claudio Pozzi have no Conflict of interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Central Ethics Committee of Milan Area n\u00b0 3, register number 113\u2013032017, and was conducted according to the tenets of the Declaration of Helsinki: 113\u2013032017, approval was received on 5 April, 2017) and then by the local ethics committees of the participating centres.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required due to the nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}}]}}